Side-by-side · Research reference
DihexavsPNC-27
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED7/28 cited
BAnimal-StrongHUMAN-REVIEWED18/41 cited
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
01Mechanism of Action
Parameter
Dihexa
PNC-27
Primary target
c-Met receptor (HGF receptor tyrosine kinase)
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
Pathway
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
Downstream effect
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Feedback intact?
—
N/A — cytotoxic mechanism, not signaling modulation
Origin
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Antibody development
—
—
02Dosage Protocols
Parameter
Dihexa
PNC-27
Human dosing
Not established — no human trials
—
Animal studies
Mouse/rat models only — dosing not translatable to humans
—
Evidence basis
Pre-clinical / Rodent models
Pre-clinical / In vitro
Clinical status
No Phase 1, 2, or 3 trials published
Pre-clinical only — no human trials
In vitro and animal model data only.
In vitro concentrations
—
10–100 μM range
Effective concentrations in cell culture studies.
Shorter analogue
—
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
03Metabolic / Fat Loss Evidence
Parameter
Dihexa
PNC-27
Fat loss mechanism
—
None — cytotoxic anticancer agent
04Side Effects & Safety
Parameter
Dihexa
PNC-27
Human safety data
None available — no human clinical trials
None available — no human trials conducted
Theoretical c-Met risks
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
—
Pre-clinical tolerability
Not systematically reported in available studies
—
Normal cell selectivity
—
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
Cancer cell specificity
—
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
Mitochondrial effects
—
Secondary mitochondrial membrane disruption in cancer cells
Absolute Contraindications
Dihexa
- ·Not approved for human use — research compound only
PNC-27
- ·Human use — no clinical trials or safety data
Relative Contraindications
Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
PNC-27
—05Administration Protocol
Parameter
Dihexa
PNC-27
1. Human administration
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
2. Legal status
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
3. Fluorescent labeling studies
—
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
4. Membrane HDM-2 requirement
—
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.